Henry Meds is among the largest compounded-GLP-1 telehealth operations. It advertises a low starting price, and its own page says the price varies by treatment plan and dosing. Its July 2026 review score is 78/100 (six-criterion rubric; v4.1 re-score pending).
July 2026 score breakdown — 78/100
| Criterion | Max | Henry Meds | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 15 | Dose-step with significant maintenance-dose upcharges; starting-price advertising understates actual annual cost. |
| 2. Pharmacy sourcing | 20 | 14 | Pharmacy partnerships exist; disclosure consistency variable. |
| 3. Clinical oversight | 15 | 13 | Clinical model present; Medical Director disclosure thinner than category leaders. |
| 4. Regulatory clarity | 15 | 13 | July 2026 notes (not re-verified): regulatory disclosures as published then. |
| 5. Patient experience | 15 | 13 | Functional intake; coaching not included; cancellation friction reported. |
| 6. Evidence quality | 10 | 10 | Claims appropriately sourced. |
| Total | 100 | 78 | Rubric application as of July 8, 2026. |
Strengths
- Low advertised starting price: “starts at $179/month” for GLP-1 care, including provider visits, medication, supplies and ongoing support (read October 15, 2026 on henrymeds.com; the medication is not named).
- Large operation with substantial clinical infrastructure.
- All 50 states.
- Multiple pharmacy partnerships.
Weaknesses
- Dose-step pricing structure — significant upcharges at higher dose tiers. Maintenance pricing not transparent in initial marketing.
- Medical Director disclosure thinner than category leaders.
- Pharmacy partner naming variable across product paths.
- No included 1:1 coaching or nutrition plan.
- Cancellation flow has historically been a friction point in reader reports.
Who should pick Henry Meds
- Patients who will stay at lower dose tiers (some sema patients respond fully at 1.0 mg).
- Patients prioritizing starting-price minimization specifically.
- Patients comfortable with a more transactional model.
Who should look elsewhere
- Patients who will reach maintenance dose (most do) and want predictable pricing.
- Patients prioritizing pharmacy disclosure depth.
- Patients who want included coaching.
How Henry Meds compares with our editor's pick
NexLife is our editor's pick at 94/100 on methodology v4.1; Henry Meds's 78/100 comes from the July 2026 review under the earlier six-criterion rubric, and its v4.1 re-score is pending. See our direct comparison: NexLife vs Henry Meds. NexLife lists compounded semaglutide at $109 a month month to month ($95 on a 12-month plan) and tirzepatide at $129 ($115 on a 12-month plan), the same at every dose with no membership (nexlife.us, read November 6, 2026). Henry Meds printed only a starting price that day, so a maintenance-dose comparison is not possible from its public pages. NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA).
Our editor's pick is NexLife at 94/100 (v4.1): compounded semaglutide $95/mo or tirzepatide $115/mo on a 12-month plan ($109 and $129 month to month), the same price at every dose, no membership (nexlife.us, read November 6, 2026). See full NexLife review →
Frequently asked
Is Henry Meds' starting price what I will pay?
Not necessarily. On October 15, 2026 Henry Meds' GLP-1 page said the price “varies by treatment plan and dosing, but starts at $179/month”. Most patients move up in dose, so ask for the price at your expected maintenance dose before enrolling.
Annual cost at maintenance?
Not verifiable from Henry Meds' public pages on October 15, 2026, which printed only the “starts at $179/month” figure. At that starting figure a year would cost $2,148; the price at maintenance doses may be higher.
Are they trustworthy?
It's a real operation. The transparency criticism is about the dose-step pricing structure, not about clinical legitimacy.